Search TXG
10x Genomics, Inc.
Nasdaq · CIK 1770787
Last close93.5
Daily change+4.74 (5.34%)
10 Years gain+77.25%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
TXG · STANDARD
SIC 3826 · Laboratory Analytical Instruments · Fiscal year end 1231
Fundamental
47.1Momentum
100.0Acceleration
100.0Confidence
91.0Annual Revenue9
Quarterly Revenue28
Annual CFO9
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth5.9 / 25
Quality13.1 / 25
Capital Efficiency6.4 / 20
Balance Sheet15.0 / 15
Shareholder Economics2.8 / 10
Forward Indicators3.9 / 5
Signals
Gross margin expansionGross margin improved by 3.0999 percentage points.
Operating leverageOperating margin improved by 24.4349 percentage points.
ROIC expansionROIC improved by 21.3368 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Key Metrics
Revenue Growth TTM3.85%OK
Revenue CAGR 3Y7.57%OK
Gross Margin71.19%OK
Operating Margin-6.21%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-6.57%OK
Incremental Operating Margin 3Y60.14%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y6.02%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $642.82M | $443.88M | -$60.99M | $136.05M | $130.12M | 69.05% | -9.49% | 20.24% | -16.34% | 124.75M |
| 2025 FY Dec 31, 2024 | $610.79M | $414.48M | -$194.56M | $6.66M | -$5.73M | 67.86% | -31.85% | -0.94% | -45.94% | 120.45M |
| 2025 FY Dec 31, 2023 | $618.73M | $409.31M | -$265.33M | -$15.20M | -$63.80M | 66.15% | -42.88% | -10.31% | -57.58% | 117.17M |
| 2024 FY Dec 31, 2022 | $516.41M | $396.02M | -$167.94M | -$33.61M | -$165.27M | 76.69% | -32.52% | -32% | -43.8% | 113.86M |
| 2023 FY Dec 31, 2021 | $490.49M | $416.40M | -$52.25M | -$21.37M | -$122.65M | 84.89% | -10.65% | -25.01% | -27.02% | 110.35M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $623.79M | sum latest 4 fiscal quarters Revenue | OK | 0001628280-26-054491, 0001628280-25-050332 |
| Revenue Growth TTM | 3.85% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001628280-26-054491, 0001628280-25-050332 |
| Revenue CAGR 3Y | 7.57% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001628280-26-007822 |
| Revenue CAGR 5Y | 16.55% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001628280-26-007822 |
| Gross Profit CAGR 3Y | 3.88% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001628280-26-007822 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001628280-26-054491, 0001628280-25-050332 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 71.19% | Gross Profit / Revenue | OK | 0001628280-26-054491, 0001628280-25-050332 |
| Operating Margin | -6.21% | Operating Income / Revenue | OK | 0001628280-26-054491, 0001628280-25-050332 |
| ROIC | -6.57% | NOPAT / Average Invested Capital | OK | 0001628280-26-054491, 0001628280-25-050332 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001628280-26-054491 |
| Current Ratio | 5.69x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $4.80 | Revenue / Diluted Shares | OK | 0001628280-26-054491, 0001628280-25-050332 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |